The BENeFiTS Trial in Beta Thalassemia Intermedia
NCT04432623
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
ENROLLING_BY_INVITATION
Status
36
Enrollment
OTHER
Sponsor class
Conditions
Beta Thalassemia Intermedia
Sickle Cell Disease
Interventions
DRUG:
Benserazide Only Product
Sponsor
Phoenicia BioScience
Collaborators
[object Object]